MasterCard Inc vs Zimmer Biomet Holdings Inc — how do they compare? MasterCard Inc trades at $558.92 (market cap $491.83B), while Zimmer Biomet Holdings Inc trades at $97.27 (market cap $18.55B). The key difference: MasterCard Inc is far larger — about 26.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| MA | ZBH | |
|---|---|---|
Market Cap | $491.83B | $18.55B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $107.71 |
52-Week Low | $471.55 | $79.58 |
Enterprise Value | $504.86B | $25.61B |
Dividend Yield | 0.62% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $563.17, up 0.04% today, with a bullish technical signal and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and net income margins above 45%. Recent earnings beats and a consensus price target of $660.85 reflect optimism, though high valuation ratios like a P/E of 30.98 warrant caution.
Outlook is positive due to consistent earnings growth, expanding digital payment initiatives, and analyst buy ratings. Risks include competitive pressures from new payment technologies and regulatory scrutiny. The stock offers upside potential but requires monitoring of valuation and market shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →